Both in Pharmaceuticals
Arbutus Biopharma vs Alumis
Over the past year ABUS returned +5.2% and ALMS returned +84.6%; their daily moves had a correlation of 0.15.
ABUS +5.2% ALMS +84.6%Growth of $1, one year, split-adjusted
| Metric | ABUS | ALMS |
|---|---|---|
| Price | $4.69 | $7.29 |
| Market cap | $929.1M | $943.6M |
| Today | −3.50% | +1.82% |
| 1 month | −7.5% | −67.4% |
| 6 months | +9.1% | −63.9% |
| Year to date | −2.5% | −25.3% |
| 1 year | +6.3% | +80.0% |
| Revenue growth (YoY) | −90.6% | −37.7% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −512.0% | −8557.2% |
| P/E (TTM) | 6.1× | — |
| Price / sales | 5.1× | 127.5× |
| Net cash | $89.5M | $502.3M |
| Dividend yield | — | — |
| Volatility (60d) | 38.9% | 182.3% |
| Short % of float | 11.8% | 8.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).